The deadliest brain cancer may have found an unexpected metabolic accomplice in the cells meant to support healthy neurons. This discovery reveals how glioblastoma hijacks surrounding astrocytes to create a cholesterol-rich environment that accelerates tumor growth, potentially opening new therapeutic pathways for a cancer with few treatment options.
The research identifies a molecular switch in tumor-associated astrocytes where the RNA-binding protein QKI shifts from its normal QKI-6 form to the QKI-5 isoform. This altered protein then partners with SREBP2, a master regulator of cholesterol metabolism, dramatically ramping up cholesterol synthesis in astrocytes. The tumor essentially reprograms these brain support cells into cholesterol factories, creating nutrient-dense conditions that fuel malignant growth. Blocking either QKI-5 or SREBP2 signaling reduced tumor-supportive effects in laboratory models.
This finding challenges conventional thinking about cancer metabolism by highlighting how tumors manipulate their cellular neighborhood rather than just their own metabolism. The QKI-5/SREBP2 axis represents a vulnerability that could be therapeutically exploited, particularly since cholesterol synthesis inhibitors already exist clinically. However, the challenge lies in selectively targeting this pathway in tumor-associated astrocytes without disrupting normal brain cholesterol metabolism, which is essential for neuronal function. The research also raises questions about whether similar metabolic hijacking occurs in other brain cancers or whether astrocyte reprogramming contributes to treatment resistance. While promising, this single study requires validation in larger cohorts and careful safety evaluation before clinical translation.